Richa Tripathi1, Stephen G Reich2, Laura Scorr1, Elizabeth Guardiani3, Stewart A Factor1. 1. Department of Neurology Emory University School of Medicine Atlanta Georgia USA. 2. Department of Neurology University of Maryland School of Medicine Baltimore Maryland USA. 3. Department of Otorhinolaryngology-Head & Neck Surgery University of Maryland School of Medicine Baltimore Maryland USA.
Abstract
INTRODUCTION: Tardive syndrome (TS) is an often irreversible movement disorder caused by dopamine receptor-blocking agents (DRBAs). Although TS are well recognized to occur with typical antipsychotics, less well appreciated is that atypical antipsychotics also carry a risk of TS. METHODS: Case series. RESULTS: We describe 4 patients who developed tardive dystonia, tardive akathisia, and drug-induced parkinsonism with the use of the atypical antipsychotic, lurasidone, which was U.S. Food and Drug Administration approved in 2013 for use in bipolar disorder and schizophrenia. CONCLUSION: Movement disorders are reported as a rare side effect of lurasidone, and, as such, prescribers may perceive a false sense of security regarding this potential complication. Our cases indicate that this relatively new atypical antipsychotic may cause irreversible disabling TS as well as parkinsonism. Caution must be taken when prescribing lurasidone.
INTRODUCTION: Tardive syndrome (TS) is an often irreversible movement disorder caused by dopamine receptor-blocking agents (DRBAs). Although TS are well recognized to occur with typical antipsychotics, less well appreciated is that atypical antipsychotics also carry a risk of TS. METHODS: Case series. RESULTS: We describe 4 patients who developed tardive dystonia, tardive akathisia, and drug-induced parkinsonism with the use of the atypical antipsychotic, lurasidone, which was U.S. Food and Drug Administration approved in 2013 for use in bipolar disorder and schizophrenia. CONCLUSION: Movement disorders are reported as a rare side effect of lurasidone, and, as such, prescribers may perceive a false sense of security regarding this potential complication. Our cases indicate that this relatively new atypical antipsychotic may cause irreversible disabling TS as well as parkinsonism. Caution must be taken when prescribing lurasidone.
Authors: Margaret G Woerner; Christoph U Correll; Jose Ma J Alvir; Blaine Greenwald; Howard Delman; John M Kane Journal: Neuropsychopharmacology Date: 2011-04-20 Impact factor: 7.853
Authors: Stefan Leucht; Andrea Cipriani; Loukia Spineli; Dimitris Mavridis; Deniz Orey; Franziska Richter; Myrto Samara; Corrado Barbui; Rolf R Engel; John R Geddes; Werner Kissling; Marko Paul Stapf; Bettina Lässig; Georgia Salanti; John M Davis Journal: Lancet Date: 2013-06-27 Impact factor: 79.321
Authors: Matthew A Stults-Kolehmainen; Miguel Blacutt; John B Bartholomew; Daniel Boullosa; Petr Janata; Brian B Koo; Paul C McKee; Regina Casper; Christopher J Budnick; Todd A Gilson; Rebekah L Blakemore; Alberto Filgueiras; Susannah L Williamson; Nicholas SantaBarbara; Jessica L Barker; Fabio Amador Bueno; Jennifer Heldring; Garrett I Ash Journal: Front Psychol Date: 2022-07-11